Cargando…

Castration-resistant prostate cancer: potential targets and therapies

The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it imposs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parray, Aijaz, Siddique, Hifzur R, Nanda, Sanjeev, Konety, Badrinath R, Saleem, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430091/ https://www.ncbi.nlm.nih.gov/pubmed/22956858 http://dx.doi.org/10.2147/BTT.S23954

Ejemplares similares

BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013)

Correction: BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013)

BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013)

Differential Effects of Genistein on Prostate Cancer Cells Depend on Mutational Status of the Androgen Receptor
por: Mahmoud, Abeer M., et al.
Publicado: (2013)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Preface to “Current and Future Topics on Prostate Cancer”
por: Konety, Badrinath R., et al.
Publicado: (2021)

Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression()
por: Ganaie, Arsheed A., et al.
Publicado: (2019)

Contemporary Management of Prostate Cancer
por: Cotter, Katherine, et al.
Publicado: (2016)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
por: Aggarwal, Rahul, et al.
Publicado: (2011)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

Targeting the MLL complex in castration resistant prostate cancer
por: Malik, Rohit, et al.
Publicado: (2015)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
por: Beer, Tomasz M., et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Targeting hexokinase 2 in castration-resistant prostate cancer
por: Deng, Yibin, et al.
Publicado: (2015)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2
por: Siddique, Abu Bakar, et al.
Publicado: (2022)

Castration-resistant prostate cancer: systemic therapy in 2012
por: Maluf, Fernando C., et al.
Publicado: (2012)

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
por: Liu, Hsin-Ho, et al.
Publicado: (2014)

Non-muscle invasive bladder cancer risk stratification
por: Isharwal, Sumit, et al.
Publicado: (2015)

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
por: Moon, Sue Jin, et al.
Publicado: (2021)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Targeting the adaptive molecular landscape of castration-resistant prostate cancer
por: Wyatt, Alexander W, et al.
Publicado: (2015)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012)

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
por: Yin, Lina, et al.
Publicado: (2013)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

Molecular Insight into Prostate Cancer: Preventive Role of Selective Bioactive Molecules
por: Jameel, Mohd, et al.
Publicado: (2023)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
por: Patel, Jesal C., et al.
Publicado: (2013)

STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer
por: Mohanty, Sambit K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rh6d43i2irvch5nqctk1vrg3en